An error has occurred.

Odd number of elements in hash assignment at useradmin.pm line 79.

Prospect News has been notified.

Content-type: text/html; charset=ISO-8859-1 Prospect News: Prospect News

E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers H > Headlines for Human Genome Sciences Inc. > News item
Published on 11/1/2006 in the Prospect News Biotech Daily.

JMP keeps Human Genome at market outperform

Human Genome Sciences, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at market outperform with a $15 price target after the company presented encouraging interim data from its phase 2 trials of Albuferon in treatment-naïve and treatment-failure hepatitis C virus patients. Albuferon demonstrated at least a comparable level of efficacy to pegylated interferon at week 24 with fewer injections, according to the analyst. Shares of the Rockville, Md.-based biopharmaceutical company were down 20 cents, or 1.50%, at $13.15. (Nasdaq: HGSI)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.